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Elizabeth G. Ryan1,2* , Julie Bruce1, Andrew J. Metcalfe1,3, Nigel Stallard4, Sarah E. Lamb1,5, Kert Viele6,
Duncan Young7 and Simon Gates1,2Abstract
Background: Bayesian adaptive designs can improve the efficiency of trials, and lead to trials that can produce
high quality evidence more quickly, with fewer patients and lower costs than traditional methods. The aim of this
work was to determine how Bayesian adaptive designs can be constructed for phase III clinical trials in critical care,
and to assess the influence that Bayesian designs would have on trial efficiency and study results.
Methods: We re-designed the High Frequency OSCillation in Acute Respiratory distress syndrome (OSCAR) trial
using Bayesian adaptive design methods, to allow for the possibility of early stopping for success or futility. We
constructed several alternative designs and studied their operating characteristics via simulation. We then
performed virtual re-executions by applying the Bayesian adaptive designs using the OSCAR data to demonstrate
the practical applicability of the designs.
Results: We constructed five alternative Bayesian adaptive designs and identified a preferred design based on the
simulated operating characteristics, which had similar power to the original design but recruited fewer patients on
average. The virtual re-executions showed the Bayesian sequential approach and original OSCAR trial yielded similar
trial conclusions. However, using a Bayesian sequential design could have led to a reduced sample size and earlier
completion of the trial.
Conclusions: Using the OSCAR trial as an example, this case study found that Bayesian adaptive designs can be
constructed for phase III critical care trials. If the OSCAR trial had been run using one of the proposed Bayesian
adaptive designs, it would have terminated at a smaller sample size with fewer deaths in the trial, whilst reaching
the same conclusions. We recommend the wider use of Bayesian adaptive approaches in phase III clinical trials.
Trial registration: OSCAR Trial registration ISRCTN, ISRCTN10416500. Retrospectively registered 13 June 2007.
Keywords: Bayesian sequential design, Interim analyses, Randomised controlled trials, Critical careBackground
Phase III randomised controlled trials (RCTs) are typically
long and expensive, restricting their use and resulting in
long lead times to answer important clinical questions [1].
Traditional phase III design methods require specification
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ders have recognised the need to use more efficient trial
designs, yet the majority of trials continue to use trad-
itional methods. Adaptive and sequential trial designs have
been described and even recommended by bodies such as
the US Food and Drug Administration [2], but their use
remains sporadic amid uncertainty about their utility out-
side of early phase trials.
Sequential adaptive designs allow repeated interim ana-
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must be specified before the trial begins. Sequential de-
signs can offer a more efficient approach for conducting
RCTs and frequently result, on average, in smaller and
shorter trials than traditional approaches. Sequential de-
signs may be implemented using frequentist methods,
which typically use null hypothesis testing, or Bayesian
methods.
The use of Bayesian statistical methods for designing
and analysing RCTs has increased (e.g., [3–6]). We con-
centrate here on Bayesian methods, because they have a
number of advantages, particularly for adaptive trials.
Bayesian statistics provide a formal method for updating
information about the treatment effect as new data are
observed, and hence are well suited to interim analyses
with accumulating information. The results of Bayesian
analyses may also be easier to interpret than frequentist
analyses as they can provide the probability of various
estimates of the unknown treatment effect. The poster-
ior distribution can also provide probabilistic statements
about other measures of interest, such as adverse event
rates and the dose-response relationship.
Bayesian approaches require specification of a prior
distribution for the possible values of the unknown
treatment effect, thereby accounting for uncertainty in
its value. The prior distribution can incorporate previous
information. Accumulating trial information is combined
with this prior to produce a posterior distribution that
summarises the current state of knowledge about the
treatment effect. This updating occurs at each interim
analysis.
The posterior distribution drives key decisions at each
interim analysis, such as stopping for trial success. Pre-
dictive probabilities can also be obtained from the pos-
terior, such as the probability that the trial will be
successful if it continues to completion. These measures,
which are more clinically relevant than p-values, can be
used to decide whether the trial should stop at an in-
terim analysis in what will be termed a “Bayesian se-
quential design” [7].
Bayesian adaptive trial designs are increasingly being
used in early phase trials, but their use in phase III trials
is more limited. The few published works mostly consist
of trial protocols [8] or are re-executions of completed
traditionally-designed trials using Bayesian adaptive de-
signs for comparative purposes (e.g., [9–12]). Few pub-
lished phase III trials have used Bayesian adaptive
methods from the design phase (e.g., [3, 5, 6]).
The aim of this work was to explore the implementation
of Bayesian sequential designs for phase III trials in critical
care. Using an example from a recent critical care trial, we
demonstrate how a Bayesian sequential design can be con-
structed, and illustrate the choices required during the de-
sign phase. The operating characteristics of the designswere studied via simulation and virtual re-executions of
the trial were performed using the Bayesian designs and
actual trial data. These were conducted to establish the ef-
ficiency of such designs, and demonstrate how these de-
signs can be implemented and the decisions that would be
made in a real-world trial during the interim analyses.
Materials and methods
Case study
The High Frequency OSCillation in Acute Respiratory
distress syndrome (ARDS) study (OSCAR) [13] com-
pared conventional positive pressure ventilation (con-
trol) with high frequency oscillatory ventilation (HFOV)
in adults with ARDS. The primary outcome was mortal-
ity at 30 days. The planned sample size was 1006 pa-
tients (503 in each arm). This gave 80% power to detect
a 9% reduction from a control group 30-day mortality of
45% with a significance level of 5%, assuming 3% drop-
out. Recruitment occurred from 7 December 2007 to 31
July 2012.
Two formal interim analyses were planned in the
OSCAR trial at approximately one third and two thirds
of the way through recruitment. The design allowed for
an additional interim analysis halfway through recruit-
ment if the Data Monitoring and Ethics Committee
(DMEC) requested closer monitoring. No formal
stopping rules were used, but O’Brien-Fleming
alpha-spending functions were used to provide guideline
critical values for early success stopping and control type
I error. These values were calculated for designs where
two or three interim analyses may be performed. The
trial could be stopped or modified by the DMEC if the
treatments were convincingly different in terms of
30-day mortality, or for safety reasons. The DMEC re-
quested sample size re-estimation to be performed at a
planned interim analysis, due to slow recruitment. The
trial statistician became unblind to the control arm pri-
mary outcome data and calculated a revised sample size
of 401 patients per arm. This calculation assumed a 10%
absolute change in mortality, with 80% power, a 5% sig-
nificance level, and 3% dropout.
OSCAR randomised 795 patients from 29 hospitals
and did not find any evidence that HFOV was superior
in the primary outcome: 166/398 (41.7%) HFOV patients
and 163/397 (41.1%) control patients died within
30-days (p = 0.85).
Potential adaptations and candidate designs
Alternative Bayesian designs for the OSCAR trial were
constructed by identifying adaptations, independently of
the trial data, to improve the trial’s efficiency. The
OSCAR trial allowed for early success stopping but did
not allow early stopping for statistical futility. Early stop-
ping for statistical futility can be useful in some trials as
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more promising treatments and prevent patients from
being given an ineffective experimental treatment. The
Bayesian sequential designs allowed early stopping for
lack of benefit or evidence of success. The number and
timing of the interim analyses were investigated. Interim
analyses could occur based on either calendar time or
number of patients recruited.
The designs were constructed by a statistician (EGR)
who was blind to the trial results and relied on the
OSCAR protocol and statistical analysis plan. Feedback
was provided from two clinical academics with experi-
ence in running RCTs (JB and AJM) who were also inde-
pendent from the original trial and blinded to the
results.
The maximum sample size was specified to be the
same as the original planned sample size (N = 1006). The
clinical academics provided key information on the min-
imal sample size for interpretability and on logistics.
They indicated that success stopping should not occur
before enrolling half of the original proposed sample size
and that more than three interim analyses would be too
burdensome. This led to a final candidate set of six de-
signs (see Table 1) including a non-adaptive/fixed design
with a Bayesian final analysis (Design 1) for comparative
purposes. The stopping boundaries in Table 1 are de-
scribed in the “Decision criteria” section.
Software and simulation settings
Simulations of the trial designs were performed using
the Fixed and Adaptive Clinical Trial Simulator (FACTS)Table 1 Candidate Bayesian sequential designs generated for OSCA
Design Interim Timing of interim
(information fraction)a
Can stop for su
1 NA (fixed design) NA NA
2 1 250 (1/4) No
2 500 (1/2) Yes
3 750 (3/4) Yes
3 1 335 (1/3) No
2 670 (2/3) Yes
4 1 335 (1/3) No
2 500 (1/2) Yes
3 670 (2/3) Yes
5 1 503 (1/2) Yes
2 755 (3/4) Yes
6 1 503 (1/2) Yes
2 755 (3/4) Yes
3 880 (7/8) Yes
aThe timing of the interims was based on the number of patients recruited
bSi is the stopping boundary for success at the i-th interim analysis.
c Fi is the stopp
are described in the “Decision criteria” sectionprogram version 6.1 [14]. For each design 10,000 ex-
ample trials were simulated assuming a true effect size.
These simulations allowed the distribution of final sam-
ple size and duration to be estimated, and quantified
type I error and power. The simulations also provided
insights into how the operating characteristics were af-
fected if the trial conditions were not as expected, e.g.,
slower recruitment, or unexpected harm.
The Bayesian sequential designs were constructed as
one-sided superiority studies as we were interested in
showing reduction in mortality in HFOV over the control.
A range of plausible scenarios were simulated for each de-
sign to investigate the operating characteristics of the de-
signs under a range of true effect sizes (see Table 2). There
was some uncertainty regarding the control primary out-
come rate, so this rate was varied in the plausible scenarios.
The recruitment rate was simulated in FACTS using a
mean of 5.5 participants/week, based on the original pro-
jected recruitment rates for OSCAR. The same assumed
dropout rate was used as for OSCAR. The operating char-
acteristics were also studied assuming slower recruitment
(2/week), faster recruitment (11/week), and no dropouts.
Non-informative prior distributions were used for the
primary outcome rate for each arm, corresponding to all
response rates between 0 and 100% being equally likely.
More informative (and more realistic) priors based on pre-
vious studies were also investigated (see Additional file 1).
Decision criteria
“Trial success” was defined as declaring superiority of
HFOV. The stopping criteria for statistical futility wereR
ccess Can stop for futility Success stopping
boundariesb
Futility stopping
boundariesc
NA NA NA
Yes NA F1 = 0.05
Yes S2 = 0.99 F2 = 0.1
Yes S3 = 0.98 F3 = 0.15
Yes NA F1 = 0.05
Yes S2 = 0.99 F2 = 0.1
Yes NA F1 = 0.05
Yes S2 = 0.99 F2 = 0.1
Yes S3 = 0.98 F3 = 0.15
Yes S1 = 0.99 F1 = 0.05
Yes S2 = 0.98 F2 = 0.1
Yes S1 = 0.99 F1 = 0.05
Yes S2 = 0.98 F2 = 0.1
Yes S3 = 0.98 F3 = 0.15
ing boundary for futility at the i-th interim analysis. The stopping boundaries
Table 2 Operating characteristics for the proposed Bayesian sequential designs for the OSCAR triala
Design Scenario: control vs HFOV
primary outcome rate
Average
duration
(weeks)
Average sample
size (SD)
Proportion stopped
early for success
Overall
Proportion
Successful b
Proportion
stopped early
for futility
Design 1: Fixed design No difference: 45% vs 45% 196 1006 (0) NA 0.0283 NA
Target difference: 45% vs 36% 196 1006 (0) NA 0.8219 NA
Small difference: 45% vs 40% 196 1006 (0) NA 0.3503 NA
Large difference: 45% vs 30% 196 1006 (0) NA 0.9979 NA
Treatment harmful: 45% vs 50% 196 1006 (0) NA 0.0003 NA
Design 2: Interim analysis
at 250, 500 and 750 patients
No difference: 45% vs 45% 103 519 (236) 0.0123 0.0268 0.8956
Target difference: 45% vs 36% 145 730 (227) 0.5319 0.7793 0.1434
Small difference: 45% vs 40% 141 719 (260) 0.1607 0.3302 0.4828
Large difference: 45% vs 30% 114 560 (127) 0.9592 0.9932 0.0058
Treatment harmful: 45% vs 50% 75 367 (155) 0.0004 0.0004 0.9949
Design 3: Interim analysis at
335 and 670 patients
No difference: 45% vs 45% 130 664 (207) 0.0070 0.0264 0.8123
Target difference: 45% vs 36% 163 828 (179) 0.4314 0.8079 0.0829
Small difference: 45% vs 40% 161 825 (207) 0.1151 0.3431 0.3593
Large difference: 45% vs 30% 139 696 (90) 0.9214 0.9971 0.0019
Treatment harmful: 45% vs 50% 109 555 (170) 0.0000 0.0005 0.9841
Design 4: Interim analysis at 335,
500 and 670 patients
No difference: 45% vs 45% 112 564 (202) 0.0087 0.0229 0.8578
Target difference: 45% vs 36% 147 741 (230) 0.4723 0.7873 0.1227
Small difference: 45% vs 40% 146 742 (242) 0.1362 0.3334 0.4371
Large difference: 45% vs 30% 114 557 (131) 0.9334 0.9958 0.0033
Treatment harmful: 45% vs 50% 91 454 (108) 0.0002 0.0003 0.9895
Design 5: Interim analysis at
503 and 755 patients
No difference: 45% vs 45% 138 712 (158) 0.0099 0.0249 0.8637
Target difference: 45% vs 36% 160 812 (176) 0.5237 0.813 0.0922
Small difference: 45% vs 40% 163 834 (174) 0.1501 0.3426 0.4062
Large difference: 45% vs 30% 134 667 (139) 0.9596 0.9968 0.0015
Treatment harmful: 45% vs 50% 126 645 (129) 0.0002 0.0005 0.9915
Design 6: Interim analysis at
503, 755 and 880 patients
No difference: 45% vs 45% 136 702 (143) 0.0130 0.0270 0.9381
Target difference: 45% vs 36% 158 792 (159) 0.6320 0.7990 0.1415
Small difference: 45% vs 40% 158 810 (156) 0.2035 0.3376 0.5420
Large difference: 45% vs 30% 134 664 (132) 0.9847 0.9966 0.0027
Treatment harmful: 45% vs 50% 127 644 (127) 0.0002 0.0005 0.9972
aThe “proportions” in columns 5–7 refer to the proportion of the 10, 000 simulated trials for each scenario, and the averages and standard deviations (SD) are over
the 10, 000 simulated trials. bThe one-sided simulated type I error is italicised; the power is boldfaced and italicised
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cess at the maximum sample size, which is denoted by
Pmax. Pmax incorporates accumulated complete data, un-
certainty in patients enrolled without complete
follow-up, and uncertainty in future patients up to the
maximum sample size [9]. The trial was stopped early
for futility if Pmax was less than a futility threshold Fi at
interim analysis i. For the purposes of simulating trial
duration, if a trial stopped for futility the trial was as-
sumed to cease immediately. If the intervention was
causing harm, then the trial would be stopped for “futil-
ity” at the interim analyses.The stopping criteria for success were based on the
posterior predictive probability of trial success at the
current sample size, after accounting for uncertainty
in enrolled patients without complete follow-up. If
this probability, Pcurr, was greater than the success
threshold Si at interim analysis i, accrual stopped for
success. All incomplete patients were followed up,
after which the final analysis was conducted. Operat-
ing characteristics were calculated assuming the futil-
ity and success stopping rules would always be
followed. The original OSCAR trial did not have
binding stopping rules.
Ryan et al. BMC Medical Research Methodology           (2019) 19:99 Page 5 of 10Using values based on previous studies [9, 10, 15] a
range of potential success and futility threshold values
were explored. For the candidate designs in Table 1,
threshold values were chosen that produced similar
power to the original design and a one-sided type I error
of approximately 2.5%. Table 1 gives the stopping
boundaries for each design.
The trial was deemed successful at the final analysis if
the posterior probability that HFOV had a lower 30-day
mortality rate was above 0.975. This value was chosen
based on the clinical academics’ preferences and by con-
sidering the power and simulated type I error it pro-
duced. The same value was used for each Bayesian
design.
The type I error was calculated from the simulations
under the null hypothesis scenario of no difference, esti-
mating the type I error rate as the proportion of such
simulations that falsely declared HFOV superior. The
power was calculated as the proportion of simulations
that concluded that HFOV was superior under the target
difference of 9%.
Identification of preferred design
The designs’ operating characteristics were presented to
the clinical academics to identify a preferred design that
they felt could have been implemented. It was desirable
to have a design which offered high power, low type I
error, and minimised the sample size. These present a
trade-off as designs which aggressively minimise sample
size may result in lower power.
Virtual re-execution of designs
A virtual re-execution of the OSCAR trial was per-
formed to illustrate the application of the Bayesian se-
quential designs to a real-world trial. The trial data were
read into FACTS and each of the Bayesian sequential de-
signs were implemented. The trial data were read in
using the original sequence of patients in recruitment
order with the interim analyses being performed after
the appropriate number of recruits for each design. At
each interim analysis, accumulated data were analysed to
determine whether the trial should be terminated early.
It was assumed that there were no delays in having the
endpoint data available for analysis. These re-executions
represent the analysis of a single realisation of the trial.
If a different trial dataset had been used, different con-
clusions would have been drawn from using these par-
ticular Bayesian designs. The OSCAR trial data
represent the only existing dataset of patients that were
actually recruited to this trial, in contrast to simulated
datasets, which may fail to capture some important as-
pect. The virtual re-executions therefore show what
would have happened if a different trial design had been
used when running the OSCAR trial.Results
Design simulations and operating characteristics
Table 2 presents the average sample size, average dur-
ation, type I error, and power for each design and sce-
nario. Distributions for the sample size and study
duration over the 10,000 simulations are shown in Add-
itional file 2: Figure S1 and Figure S2. Table 2 also pre-
sents the proportion of simulations stopped early for
success or futility. There was little variation in the oper-
ating characteristics when the prior or accrual assump-
tions were varied (results not presented).
The Bayesian sequential designs had around 80%
power and acceptable simulated type I errors of 2.3—
2.7%, while saving on the sample size. Under the null
scenario, the average sample sizes were reduced by ap-
proximately 300–500 patients. Under the target differ-
ence of a 9% reduction in 30-day mortality, the average
sample sizes were reduced by approximately 200–300
patients. Similar sample size reductions were observed
when a small positive effect was assumed. The average
sample size was reduced by 300–450 patients when a
large positive effect was assumed.
The designs performed well in terms of safety and effi-
ciency, in that they stopped earliest for a harmful effect,
followed by either a large positive effect or no effect.
Uncertainty in the control arm rate had little impact
(see in Additional file 3: Table S1).
Design 5, which had interim analyses at 503 and 755
patients recruited, was chosen independently by JB and
AJM, since it had the highest power of the Bayesian de-
signs at 81.3% and a low type I error rate of 2.49%. The
clinical academics also preferred the timing of these in-
terim analyses.
Re-execution of the OSCAR trial
Interim analyses
The virtual executions of Designs 2–5 are presented in
Table 3. Design 1 (fixed design) is not presented. Design
6 was not executed as the trial would have stopped be-
fore interim analysis 3, giving the same results as Design
5. Sensitivity analyses were performed using alternatives
to the default non-informative priors, but little differ-
ences were seen between the analyses (results not
presented).
In the interim analyses, the posterior probability that
HFOV was superior ranged from 0.44–0.82 across the
different interim analysis points. As the trial progressed,
there was a decrease in the posterior predictive probabil-
ities of having a successful trial if the trial continued to
completion with 1006 patients, and all designs stopped
early for futility. The stopping boundary for futility at
the second interim analysis was 0.1 for all designs, and
was met by Designs 3, 5 and 6. Designs 2 and 4, with
the second interim analysis taken earlier, did not meet
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terim analysis. Pmax (the predictive probability of success
if the trial continued to its maximum sample size) did
not drop below 0.1 until 546 patients had been recruited
(Pmax = 0.0893 at N = 546).
Final analyses
The analyses based on the final data, including
follow-up, from each Bayesian sequential design are pre-
sented in Table 4 along with the original trial results and
the savings in recruitment for these trial data. Results
for Designs 4 and 6 are not presented as these are the
same as for Designs 3 and 5, respectively. There was lit-
tle variation in the results across the designs – the rela-
tive risks (RRs) ranged from 0.99–1.02, and the posterior
probabilities that HFOV was superior ranged from 0.40–
0.53.
The results given in Table 4 show that the
re-executions using the different designs based on this
single set of trial data reflect the operating character-
istics presented and discussed above. With the data
observed, each of the proposed Bayesian sequential
designs would have saved on overall trial duration,
sample size and number of deaths relative to the ac-
tual trial. The Bayesian sequential designs could have
shortened the trial duration by between 15 and 40
weeks and recruited 231–336 fewer patients than the
target sample size of N = 1006 and 20–125 fewer pa-
tients than the 795 that the OSCAR trial achieved.
Designs 3 and 4 performed best in terms of redu-
cing the number of patients randomised and the trial
duration by stopping the trial earliest for futility.
These are the Bayesian versions of the OSCAR design
that was originally proposed. In the re-executions, all
of the Bayesian designs would have terminated the
trial with fewer patient deaths than the trial that was
actually conducted.Table 4 Final analyses based on the resulting sample collected from
OSCAR trial Design 2
Primary outcome (control; HFOV) 163/397 (41.1%); 166/398
(41.7%)
154/377 (40.8
(41.8%)
RR (95% CI) 1.02 (0.86, 1.20) 1.02 (0.86, 1.2
Posterior probability HFOV
superior
0.46 0.40
Number of deaths in trial 329 310
Number randomiseda 795 750
Recruitment savings from original
sample size of N = 1006
211 256
Recruitment savings from achieved
OSCAR sample size of N = 795
NA 45
Accrual Duration (weeks)b 243 227
aBased on the number of patients required to trigger the interim analyses at which
for the patient that triggered the interim analysis at which the trial was stoppedCare should be taken not to over-interpret these results
since they represent the analysis of a single dataset. How-
ever, the data are the only information on patients re-
cruited to this trial that actually exists, and re-executing
the trial with alternative designs tells us how these would
have performed in reality. To fully understand the real-life
efficiency savings that these designs may lead to, they
would have to be run on a large number of trials. It should
be recognised that a large number of phase III trials fail to
detect differences between treatment arms and therefore
the example chosen is a common scenario, and more
widespread use of futility stopping would likely result in
efficiency gains across a broad portfolio of trials.Discussion
Summary
We have demonstrated how Bayesian sequential designs,
a type of adaptive design, could be implemented for a
phase III trial in acute respiratory distress syndrome
(ARDS). We outlined the process involved in construct-
ing the sequential designs, and demonstrated their oper-
ating characteristics under a range of scenarios. These
showed potential advantages over the original OSCAR
trial design. By performing virtual executions of the de-
signs using actual data from the OSCAR trial, we dem-
onstrated how decisions would be made using the
posterior predictive probability of trial success at each
interim analysis.
OSCAR is a trial where a Bayesian sequential design
could have been used as it has a relatively simple design,
short follow-up period for the primary outcome, object-
ive primary outcomes that can easily be collected, and
slow recruitment. Trials that have longer follow-up pe-
riods for the primary outcome and faster recruitment
rates are more challenging for adaptive designs as less
information may be available at each interim analysis.each design
Design 3 Design 5
%); 156/373 138/339 (40.7%); 134/331
(40.5%)
156/380 (41.1%); 157/375
(41.9%)
2) 0.99 (0.83, 1.20) 1.02 (0.86, 1.21)
0.53 0.40
272 313
670 775
336 231
125 20
203 228
the trial was stopped. bThese numbers are based on the randomisation date
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adaptations were restricted to stopping early for success
or futility. The proposed Bayesian sequential designs dif-
fered in the number and timing of their interim analyses.
Bayesian adaptive designs can be most advantageous for
trials with complex designs, such as multi-arm trials or
those with longitudinal modelling due to their ability to
deal with multiple complex decisions [16].
The OSCAR study had planned interim analyses but
no formal stopping rules. The early stopping rules in the
Bayesian sequential designs for OSCAR allowed for spe-
cification of more aggressive stopping and allowed stop-
ping for futility. This is particularly important for
interventions that appear to be harmful or are more ex-
pensive and enables patients to receive beneficial treat-
ments more quickly. The cost per patient in the OSCAR
trial was £3402, and significant savings could have been
made by stopping the trial early. The OSCAR trial did
not allow for early futility stopping and if it had done so,
our Bayesian designs may not have shown an increased
efficiency.
Not all Bayesian adaptive trials would want to incorp-
orate early stopping for futility, and the decisions to be
made at interim analyses are trial-dependent. For in-
stance, trials that plan cost-effectiveness in their primary
analysis may not want to stop early for futility, or may
wish to incorporate cost-effectiveness into their stopping
criteria.
The simulations of the Bayesian designs produced simi-
lar operating characteristics. The virtual re-executions
produced similar results to the OSCAR trial across the de-
signs for the primary outcome analysis. In practice, one
Bayesian design would have been used and the retrospect-
ive comparison of multiple designs would not be possible.
Also, designs which stop early have been shown to have
small biases in the treatment effect estimates (see, for ex-
ample, [17, 18]) compared to trials that did not stop early.
Checks for potential bias should be performed during the
simulation stage and bias-correction methods imple-
mented if necessary (e.g., [19]).
Limitations
The designs proposed in this paper are situation-specific,
as all Bayesian adaptive designs are, and cannot be gener-
alised to all phase III trials. Similar principles to those out-
lined in this study should be used when constructing
adaptive designs that are tailored to the trial aims and
clinical practicalities in other settings.
Sequential designs are well known to reduce the ex-
pected sample size, and for these trials, similar results
might have been obtained if frequentist stopping criteria
had been employed. Bayesian criteria were employed to
demonstrate their usefulness to clinicians, particularly
with regards to interpretability.The adaptive designs presented in this paper are not ne-
cessarily optimal – if different clinicians had been con-
sulted, alternative designs would have been selected. An
increase in the number of interims would have led to
smaller expected sample sizes, but at the cost of increased
operational complexity. Also, if different values had been
chosen for the stopping criteria, different decisions may
have been made at the interim analyses. For instance, if
Design 2 instead used less aggressive stopping boundaries
for futility, higher power could be obtained, whilst main-
taining the ability to stop early for harm. Selection of the
stopping boundaries involves a trade-off of the power, type
I error and expected sample size. The main benefit of this
approach is that efficient and practically relevant designs
can be generated using statistical measures that are intui-
tive to interpret.
The decisions made by the clinical academics when
constructing and choosing the designs were based on a
mixture of the statistical aspects of the designs as well as
their views about the operational factors. These included
the timings of interim analyses and concerns about the
perceived external validity of very aggressive stopping
rules when presented to a clinical audience who are
often naïve to these novel designs. These practical issues
are important to consider when such designs are pro-
posed. Operationally, interim analyses need to be ad-
equately spaced to allow time for data cleaning,
performing the analysis and presentation to DMECs and
Trial Steering Committees (TSCs). In setting the bound-
aries, it was also noted that decisions need to be taken
as to whether the analyses should be based at
pre-specified times (which are easier to manage oper-
ationally) or a pre-specified number of samples (which
are harder to manage operationally, but are easier to
manage statistically).
There are a number of practical challenges associated
with running adaptive designs in RCTs. In these ana-
lyses, we assumed there was no delay between the in-
terim analyses and stopping recruitment if the stopping
criteria were met. We also assumed that primary out-
come data were immediately available following the
30-day follow-up period. In reality, there might be slight
delays for both of these processes, particularly for the
former as the DMEC and TSC are likely to be involved.
This would decrease the savings achieved by the Bayes-
ian sequential designs.
There are also issues regarding blinding of the TSC
and DMEC to interim analysis results, and decisions re-
garding these must be made before the trial begins, as
well as decisions about whether the DMEC and TSC will
be bound by the results of the adaptive design. It may be
that the decision to stop or continue the trial is made by
the DMEC, who then convey the decision to the TSC.
The interim analyses themselves should not take long to
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can be automated.
Our Bayesian adaptive designs assumed that stopping
early for success or futility was driven by the primary
outcome. For OSCAR, the primary outcome was also a
safety outcome. If a suitable secondary outcome had
been available to use in the interim analyses, then differ-
ent decisions may have been made when considering the
trade-off between outcomes.
Part of the reason for the lack of wide scale adoption
of adaptive or sequential designs may be that investiga-
tors are not incentivised to terminate trials early. Al-
though early termination may have benefits for the
funding agency, it has little benefit for the researchers,
who may then face problems of loss of research income
and retention of staff. Furthermore, there may be criti-
cism of trials that fail to recruit their planned maximum
sample size. It is easier to apply adaptive methodologies
in multi-armed trials, where closure of arms is less con-
sequential. It is likely that a change in the funding model
for publicly funded trials is required to take full advan-
tage of innovation in trial design.
Conclusions
There is a great need for phase III trials to become more
efficient, yet the majority of clinical trials continue to
employ traditional methods. Innovation in clinical trial
design is of high importance as it can potentially im-
prove the efficiency, quality of knowledge gained, cost
and safety of clinical trials. In this work we have illus-
trated the benefits of using Bayesian sequential trial de-
signs, using a published example from respiratory
medicine, and recommend their use in the wider clinical
community.
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